Literature DB >> 10449599

BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.

M Santarosa1, R Dolcetti, M D Magri, D Crivellari, M G Tibiletti, A Gallo, S Tumolo, L Della Puppa, D Furlan, M Boiocchi, A Viel.   

Abstract

The heritable defects of BRCA1 and BRCA2 genes have been shown to predispose to breast and ovarian cancers. In a previous report, we analyzed 46 Italian families with breast and/or ovarian cancer for BRCA1 mutations. In the present study, those families and 11 others were screened for BRCA2 mutations; the newly enrolled families were also analyzed for the BRCA1 gene. The coding region and splice boundaries of BRCA2 and BRCA1 genes were assessed by the protein-truncation test and single-strand conformational polymorphism. A total of 20 different mutations were found in 21 families (37%). A total of 9 families (16%) showed mutations in the BRCA1 gene, including the one new mutation identified in this study (5382insC), and 12 families (21%) presented mutations in the BRCA2 gene. BRCA2-mutated families presented breast and ovarian cancers or breast cancers only, whereas most BRCA1-mutated families presented ovarian cancer alone or in association with breast cancer. All the BRCA2 mutations led to a truncated protein: 6 were frameshift mutations, 4 were non-sense mutations and 2 involved the intronic invariant region leading to splice variants. Therefore, in the Italian population, the cumulative proportion of BRCA1 and BRCA2 mutations was within the range observed in other studies (37%), with higher involvement of BRCA2 than of BRCA1. Many families in which no mutations were found presented a very high incidence of breast and/or ovarian cancer. Among the 36 BRCA1 and BRCA2 wild-type families, 24 presented at least 4 cancer cases, indicating the existence of other important predisposing genes. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10449599     DOI: 10.1002/(sici)1097-0215(19990924)83:1<5::aid-ijc2>3.0.co;2-u

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Authors:  Natalia Issaeva; Huw D Thomas; Tatjana Djureinovic; Tatjana Djurenovic; Janneke E Jaspers; Ivaylo Stoimenov; Suzanne Kyle; Nicholas Pedley; Ponnari Gottipati; Rafal Zur; Kate Sleeth; Vicky Chatzakos; Evan A Mulligan; Cecilia Lundin; Evgenia Gubanova; Ariena Kersbergen; Adrian L Harris; Ricky A Sharma; Sven Rottenberg; Nicola J Curtin; Thomas Helleday
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

2.  Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers.

Authors:  GianMaria Miolo; Vincenzo Canzonieri; Clelia De Giacomi; Lara Della Puppa; Riccardo Dolcetti; Davide Lombardi; Tiziana Perin; Simona Scalone; Andrea Veronesi; Alessandra Viel
Journal:  BMC Cancer       Date:  2009-10-10       Impact factor: 4.430

3.  Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.

Authors:  Ksenija Strojnik; Mateja Krajc; Vita Setrajcic Dragos; Vida Stegel; Srdjan Novakovic; Ana Blatnik
Journal:  Breast Cancer Res Treat       Date:  2021-04-23       Impact factor: 4.872

4.  The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.

Authors:  Vida Stegel; Mateja Krajc; Janez Zgajnar; Erik Teugels; Jacques De Grève; Marko Hočevar; Srdjan Novaković
Journal:  BMC Med Genet       Date:  2011-01-14       Impact factor: 2.103

5.  High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.

Authors:  Petr Pohlreich; Michal Zikan; Jana Stribrna; Zdenek Kleibl; Marketa Janatova; Jaroslav Kotlas; Jana Zidovska; Jan Novotny; Lubos Petruzelka; Csilla Szabo; Bohuslav Matous
Journal:  Breast Cancer Res       Date:  2005-07-19       Impact factor: 6.466

6.  Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy.

Authors:  GianMaria Miolo; Lara Della Puppa; Manuela Santarosa; Clelia De Giacomi; Andrea Veronesi; Ettore Bidoli; Maria Grazia Tibiletti; Alessandra Viel; Riccardo Dolcetti
Journal:  BMC Cancer       Date:  2006-06-09       Impact factor: 4.430

7.  BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome.

Authors:  Ingrid Petroni Ewald; Silvia Liliana Cossio; Edenir Inez Palmero; Manuela Pinheiro; Ivana Lucia de Oliveira Nascimento; Taisa Manuela Bonfim Machado; Kiyoko Abe Sandes; Betânia Toralles; Bernardo Garicochea; Patricia Izetti; Maria Luiza Saraiva Pereira; Hugo Bock; Fernando Regla Vargas; Miguel Ângelo Martins Moreira; Ana Peixoto; Manuel R Teixeira; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2016 Apr-Jun       Impact factor: 1.771

8.  Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.

Authors:  Giulia Cini; Massimo Mezzavilla; Lara Della Puppa; Elisa Cupelli; Alessio Fornasin; Angela Valentina D'Elia; Riccardo Dolcetti; Giuseppe Damante; Sara Bertok; Gianmaria Miolo; Roberta Maestro; Paolo de Paoli; Antonio Amoroso; Alessandra Viel
Journal:  BMC Med Genet       Date:  2016-02-06       Impact factor: 2.103

9.  Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome.

Authors:  Concetta Santonocito; Roberta Rizza; Ida Paris; Laura De Marchis; Carmela Paolillo; Giordana Tiberi; Giovanni Scambia; Ettore Capoluongo
Journal:  Cancers (Basel)       Date:  2020-05-19       Impact factor: 6.639

10.  Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.

Authors:  Mateja Krajc; Erik Teugels; Janez Zgajnar; Guido Goelen; Nikola Besic; Srdjan Novakovic; Marko Hocevar; Jacques De Grève
Journal:  BMC Med Genet       Date:  2008-09-10       Impact factor: 2.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.